|
|
 |
A financial advisor atorvastatin emc spc Revlimid plus dexamethasone helped patients live longerwithout their cancer progressing than a combination ofmelphalan, prednisone and thalidomide, Celgene said. The study,from the third and final stage of testing generally required forapproval, was in 1,623 patients. Celgene said it plans topresent further results at a medical meeting.
2021-5-19 22:01:33 |
|
|
|
